Additional Studies. During the Term and continuing [***], Corvus agrees to negotiate exclusively with Genentech for a period of [***] prior to entering into any clinical study or clinical development agreement with a Third Party involving the combination of Corvus Molecule and any PD-L1 Antagonist or PD-1 Antagonist. During such [***], the Parties shall discuss in good faith the terms and conditions for collaborating with each other to conduct further clinical studies of the Combination, including terms [***].
Additional Studies. If a Party (including its Affiliates or Sublicensees) wishes to conduct one or more additional Clinical Studies or Development activities for a CoDev Product (beyond the Pivotal Clinical Study or other Clinical Studies included in the then-current CoDev Product Plan), such Party (the “Proposing Party”) shall notify the other Party (the “Non-Proposing Party”) of such proposed studies (the “Proposed Study(ies)”) and provide the Non-Proposing Party with any Data or publications supporting any such proposal. In such event, the JDC shall consider such proposal and evaluate the supporting Data and information in good faith. If the Parties both wish to collaborate in the conduct of such Proposed Study(ies), the Proposing Party shall prepare an amendment to a CoDev Product Plan and Joint Development Budget to include the Proposed Study(ies) for review and approval by the JDC, and subsequently the JSC. If, after consideration in good faith by the JDC and the JSC, as applicable, the Parties do not, within [***] days of the first applicable JSC meeting, mutually agree to include the Proposed Study(ies) in a CoDev Product Plan, the Proposing Party may elect to conduct such rejected Proposed Study(ies) (such study(ies), in such event, “Unsponsored Work”), rather than escalate further as described in Section 3.6.2.1. Notwithstanding the foregoing, the Non-Proposing Party may, within [***] days following the failure of the JDC to mutually agreed to include the Proposed Study(ies) in a CoDev Product Plan (the “Objection Period”), provide reasonable written objection to such Unsponsored Work on the basis of likely potential Material Adverse Effect upon the procurement or maintenance of Marketing Approval or Commercialization of a CoDev Product. If the Non-Proposing Party makes such an objection, the Proposing Party shall not be permitted to proceed with such Unsponsored Work, provided that if the Proposing Party disputes the stated likely potential Material Adverse Effect upon the procurement or maintenance of Marketing Approval or Commercialization of a CoDev Product by the Unsponsored Work, then such dispute shall be subject to Accelerated Arbitration. The Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Additional Studies. 5.6.1 The Parties recognize that AstraZeneca or its Affiliates are currently in the process of negotiating or have recently executed certain Additional Studies with potential Third Party partners in relation to the Compounds. Following the Effective Date, AstraZeneca shall keep Mereo informed as to the negotiation status of such Additional Studies, if applicable, and shall [***], including by [***] Following the conclusion of such negotiations, if applicable, AstraZeneca or its Affiliates or Mereo, as agreed between the Parties, shall enter into agreements governing the conduct of such Additional Studies, provided that [***]
Additional Studies. If a Party would like to conduct additional clinical studies using the Combination, at the request of such Party, the Parties shall discuss in good faith the possibility of, and the terms and conditions for, conducting such clinical studies, including cost sharing, decision making and the supply of Compounds. This Section shall survive the expiration of this Agreement for a period of ***. *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Article 3
Additional Studies. NEOTHERAPEUTICS reserves the right, subject to the approval and oversight of the Joint Development Committee, which approval will not be unreasonably withheld, to propose additional studies of Satraplatin at its own expense.
Additional Studies. All of the restoration opportunities mentioned in this report will require further investigation and analysis to fully assess feasibility and determine actual benefits and costs. In some cases, restoration actions are recommended that may involve private properties. This plan makes no claims as to the ownership or availability of any parcel of land for restoration purposes and does not recommend takings of any private land. Restoration activities described here would be undertaken on a voluntary basis with the express permission of private property owners. Additional study, collaboration, and project planning and design would be required to ensure consensus on the restoration priorities; acquire permission or easements; and develop detailed implementation plans, budgets, schedules, and monitoring programs.
Additional Studies. The Parties may agree to undertake additional studies or pilot projects to evaluate various forms of program linkage.
Additional Studies. If required or requested for the purpose of registering and/or commercializing the Product in any particular country in the Territory, Ipsen shall be authorized to conduct the required or requested pre-clinical, clinical or other studies, including Phase IV studies (collectively “Additional Studies”), relating to the Product, subject to prior written notification to Auxilium and subject to Sections 4.5.1 and 4.5.2 below. ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.
Additional Studies. In tumour biopsies collected during surgical resection: o *** · In blood samples collected after the commencement of therapy and up until surgical resection: o *** o *** · Scale-up runs performed by the Charity for technology transfer of AST-VAC2 process · Engineering run for AST-VAC2 manufacture performed by the Charity prior to manufacture of cGMP batch of AST-VAC2 IMP · cGMP manufacturing of AST-VAC2 IMP by the Charity · Studies performed by the Charity to assess and qualify the *** used for the final production of AST-VAC2 · Studies performed by the charity to qualify the use of AST-VAC2 release assays at the Charity · In process, release, and stability testing of AST-VAC2 IMP performed by the Charity For the avoidance of doubt, all references in this Schedule 9 to anything done “by the Charity” shall be construed as including anything done on behalf of or at the instruction of the Charity. Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 24b-2 of the Exchange Act of 1934, as amended. Confidential Portions are marked: [***]. Schedule 10
Additional Studies. The Client undertakes to have carried out a soil survey and a thermal performance study and to issue them to the Architect in due time to allow him/her to carry out the Appointment in accordance with the Agreement. If unforeseen circumstances require recourse to outside Consultants (for example: structural, acoustical engineers, etc.), or that the Architect advises their appointment, the corresponding expense is charged to the Client. Guarantee of payment to Contractors The Client acknowledges to be informed of the obligation to guarantee Contractors payment of sums due when these exceed 12,000 euro under the provisions of article 1799-1 of the Civil Code. Respective obligations of the Client and Contractor when sub-contracting The Client acknowledges to be informed by the Architect of its obligations when sub-contracting in application of the 31st December 1975 Act N° 75-1334, in particular: - the Contractor who resorts to sub-contractors should have the Client’s approval and agreement of the terms of their payment. - by default to directly pay sub-contractors by delegation. The Client should require that the Contractor justifies to have supplied a joint and several guarantee obtained from a financial institution to guarantee the sums due. Client insurances The Client acknowledges to have been informed by the Architect of the obligation to subscribe, before the opening of the construction site, construction insurance for the Works in compliance with clause L 242-1 of the Insurance Code. Furthermore, the Client acknowledges to have been informed about any need to subscribe additional insurance to cover, in particular, damage to existing buildings or to adjoining premises due to the construction work. All information about guarantees and exclusions from these insurances depends solely upon competence of the insurance agent. Approval of documents prepared by the Architect The Client reviews documents that the Architect submits for approval. In compliance with clause 9, the Client approves them in due time by affixing its signature and the date on each document. This signature confirms acceptance by the Client of the Work Stage in hand, the corresponding fee and for the Appointment to proceed. If the Client refuses to give approval, it should make clear the grounds in writing within 10 days following the receipt of documents. The Client and the Architect determine together to pursue the Appointment. Any document issued by the Client should be sent to ...
